Regulatory and Safety: Obesity Drugs

November 13, 2009

Diabetes & Obesity Series


Safety and Regulatory Aspects of Obesity Drugs

Subscribe to RSS feed of this series



Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace



Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.

Others in the Series



Diabetes Resources

Associations and Societies


Clinical Trials

Obesity Resources

Articles, Multimedia


Associations and Societies

Clinical Trials

Related Content:

News